Gary, J. Kelloff
#132,261
Most Influential Person Now
Gary, J. Kelloff's AcademicInfluence.com Rankings
Gary, J. Kelloffengineering Degrees
Engineering
#4601
World Rank
#5809
Historical Rank
Biomedical Engineering
#298
World Rank
#305
Historical Rank
Gary, J. Kelloffphilosophy Degrees
Philosophy
#6482
World Rank
#9524
Historical Rank
Logic
#3639
World Rank
#4830
Historical Rank
Download Badge
Engineering Philosophy
Why Is Gary, J. Kelloff Influential?
(Suggest an Edit or Addition)Gary, J. Kelloff's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. (2000) (2515)
- Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. (1999) (648)
- Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development (2005) (632)
- The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. (2000) (502)
- Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. (2000) (496)
- Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial (2008) (460)
- Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: a review. (1990) (459)
- Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. (1995) (446)
- Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. (2000) (423)
- A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis (2002) (421)
- Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. (1993) (376)
- Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development: Recommendations of the American Association for Cancer Research Task Force on the Treatment and Prevention of Intraepithelial Neoplasia (2002) (339)
- Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. (1996) (338)
- Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. (1987) (337)
- Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis (2017) (322)
- Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. (1997) (318)
- Considerations in the development of circulating tumor cell technology for clinical use (2012) (313)
- Perspectives on cancer chemoprevention research and drug development. (2000) (310)
- Screening of potential chemopreventive agents using biochemical markers of carcinogenesis. (1994) (306)
- Effects of the phytochemicals, curcumin and quercetin, upon azoxymethane-induced colon cancer and 7,12-dimethylbenz[a]anthracene-induced mammary cancer in rats. (1996) (279)
- Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. (2000) (277)
- Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move Forward (2006) (272)
- Chemoprevention of chemically-induced mammary carcinogenesis by indole-3-carbinol. (1995) (268)
- Efficacy of potential chemopreventive agents on rat colon aberrant crypt formation and progression. (2000) (266)
- Retinoids in chemoprevention and differentiation therapy. (2000) (262)
- Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. (1990) (260)
- Cancer biomarkers: selecting the right drug for the right patient (2012) (251)
- Lipoxygenase inhibitors as potential cancer chemopreventives. (1999) (250)
- Chemopreventive drug development: perspectives and progress. (1994) (236)
- Chemoprevention of colon carcinogenesis by organosulfur compounds. (1993) (234)
- Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. (2002) (234)
- The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development (2005) (228)
- Mitigating the risk of radiation-induced cancers: limitations and paradigms in drug development (2014) (223)
- Chemoprevention of colon carcinogenesis by dietary perillyl alcohol. (1997) (215)
- Aberrant crypts as a biomarker for colon cancer: evaluation of potential chemopreventive agents in the rat. (1996) (212)
- Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400 (2015) (199)
- Chemoprevention of Colon Carcinogenesis by Dietary Administration of Piroxicam, α-Difluoromethylornithine, 16α-Fluoro-5-androsten-17-one, and Ellagic Acid Individually and in Combination (1991) (199)
- Enhancement of experimental colon cancer by genistein. (1997) (192)
- Comparative chemopreventive mechanisms of green tea, black tea and selected polyphenol extracts measured by in vitro bioassays. (2000) (189)
- Challenges in clinical prostate cancer: role of imaging. (2009) (188)
- Group-specific antigen expression during embryogenesis of the genome of the C-type RNA tumor virus: implications for ontogenesis and oncogenesis. (1970) (179)
- Prevention of cancer in the next millennium: Report of the Chemoprevention Working Group to the American Association for Cancer Research. (1999) (178)
- Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: Methods and results from the NCI chemoprevention drug development program (1994) (178)
- Chemoprevention studies of the flavonoids quercetin and rutin in normal and azoxymethane-treated mouse colon. (2000) (177)
- Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development (2004) (173)
- Mechanistic considerations in chemopreventive drug development (1994) (165)
- Progress in Cancer Chemoprevention (1999) (165)
- Calcium, vitamin D, and colon cancer. (1992) (162)
- Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. (1992) (162)
- Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy. (1992) (161)
- Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. (2000) (157)
- Use of CA-125 in Clinical Trial Evaluation of New Therapeutic Drugs for Ovarian Cancer (2004) (154)
- Risk biomarkers and current strategies for cancer chemoprevention (1996) (146)
- Cancer chemoprevention: progress and promise. (1999) (142)
- Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats. (1989) (142)
- Incidence of spontaneous neoplasms in F344 rats throughout the natural life-span. (1975) (141)
- Strategy and planning for chemopreventive drug development: Clinical development plans II (1994) (141)
- Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositol. (2000) (139)
- Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice. (1997) (133)
- Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials. (1994) (130)
- Effect of retinoids on AOM-induced colon cancer in rats: modulation of cell proliferation, apoptosis and aberrant crypt foci. (1999) (120)
- Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process. (1999) (116)
- Chemoprevention of Prostate Cancer: Concepts and Strategies (1999) (114)
- Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer. (2000) (110)
- A germ-line p53 mutation accelerates pulmonary tumorigenesis: p53-independent efficacy of chemopreventive agents green tea or dexamethasone/myo-inositol and chemotherapeutic agents taxol or adriamycin. (2000) (110)
- Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin dose. (1997) (109)
- Chemopreventive efficacy of arylalkyl isothiocyanates and N-acetylcysteine for lung tumorigenesis in Fischer rats. (1996) (109)
- Apoptosis, cell replication, and Western-style diet-induced tumorigenesis in mouse colon. (1996) (108)
- Intermittent dosing with oltipraz: relationship between chemoprevention of aflatoxin-induced tumorigenesis and induction of glutathione S-transferases. (1995) (106)
- Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. (2000) (105)
- Localization of avian tumor virus group-specific antigen in cell and virus. (1966) (102)
- Strategy and planning for chemopreventive drug development: Clinical development plans (1996) (102)
- Approaches to the development and marketing approval of drugs that prevent cancer. (1995) (101)
- Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. (1996) (101)
- Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon. (1999) (100)
- Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis. (1999) (98)
- Cancer chemoprevention agent development strategies for genistein. (1995) (96)
- Modulation of apoptosis by cigarette smoke and cancer chemopreventive agents in the respiratory tract of rats. (2001) (96)
- Chemopreventive effect of oltipraz during different stages of experimental colon carcinogenesis induced by azoxymethane in male F344 rats. (1993) (93)
- Screening for chemopreventive (anticarcinogenic) compounds in rodents. (1992) (92)
- Sex-related differences in bronchial epithelial changes associated with tobacco smoking. (1999) (91)
- Inhibition of transformation in cultured rat tracheal epithelial cells by potential chemopreventive agents. (1990) (90)
- Chemoprevention of rat prostate carcinogenesis by 9-cis-retinoic acid. (1999) (89)
- New science-based endpoints to accelerate oncology drug development. (2005) (89)
- Quantitative imaging test approval and biomarker qualification: interrelated but distinct activities. (2011) (88)
- Perspectives in cancer chemoprevention. (1997) (88)
- Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. (1996) (87)
- Concepts in cancer chemoprevention research (1990) (86)
- Inhibition of rat mammary gland chemical carcinogenesis by dietary dehydroepiandrosterone or a fluorinated analogue of dehydroepiandrosterone. (1991) (85)
- Modulation of biomarkers by chemopreventive agents in smoke-exposed rats. (2001) (84)
- Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone. (1999) (82)
- Imaging and oncologic drug development. (2006) (82)
- Evidence of Clinical Utility: An Unmet Need in Molecular Diagnostics for Patients with Cancer (2014) (82)
- Aromatase inhibitors as potential cancer chemopreventives. (1998) (81)
- Influence of N-methyl-N-nitrosourea, testosterone, and N-(4-hydroxyphenyl)-all-trans-retinamide on prostate cancer induction in Wistar-Unilever rats. (1998) (79)
- The Quantitative Imaging Network: NCI's Historical Perspective and Planned Goals. (2014) (77)
- Progress in clinical chemoprevention. (1997) (76)
- The group-specific antigen and other structural proteins of hamster and mouse C-type viruses. (1971) (75)
- Growth kinetics and chemoprevention of aberrant crypts in the rat colon (1992) (75)
- Protective action of plant polyphenols on radiation-induced chromatid breaks in cultured human cells. (1998) (73)
- Inhibition by dietary oltipraz of experimental intestinal carcinogenesis induced by azoxymethane in male F344 rats. (1991) (72)
- Modulation of azoxymethane-induced mutational activation of ras protooncogenes by chemopreventive agents in colon carcinogenesis. (1994) (72)
- Chemoprevention of OH-BBN-induced bladder cancer in mice by piroxicam. (1993) (72)
- Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, alpha-difluoromethylornithine, 16 alpha-fluoro-5-androsten-17-one, and ellagic acid individually and in combination. (1991) (72)
- The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications (2017) (71)
- Formation and persistence of nucleotide alterations in rats exposed whole-body to environmental cigarette smoke. (1999) (69)
- Chemopreventive efficacy of anethole trithione, N‐acetyl‐L‐cysteine, miconazole and phenethylisothiocyanate in the DMBA‐induced rat mammary cancer model (1997) (68)
- Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer. (2001) (68)
- Chemoprevention of MNU-induced mammary tumors in the mature rat by 4-HPR and tamoxifen. (1992) (68)
- IMMUNOLOGICAL TOLERANCE TO RNA TUMOR VIRUS GENOME EXPRESSIONS: SIGNIFICANCE OF TOLERANCE AND PRENATAL EXPRESSIONS IN EMBRYOGENESIS AND TUMORIGENESIS (1971) (67)
- Prevention by retinoids of azoxymethane-induced tumors and aberrant crypt foci and their modulation of cell proliferation in the colon of rats. (1997) (66)
- Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats. (1994) (64)
- 5-Aza-2'-deoxycytidine is chemopreventive in a 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone-induced primary mouse lung tumor model. (1999) (64)
- 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. (2001) (62)
- Progress in applied chemoprevention research. (1990) (62)
- Image morphometric nuclear grading of intraepithelial neoplastic lesions with applications to cancer chemoprevention trials. (1999) (62)
- Patterns of DNA adduct formation in liver and mammary epithelial cells of rats treated with 7,12-dimethylbenz(a)anthracene, and selective effects of chemopreventive agents. (1999) (62)
- Genetic and cellular changes in colorectal cancer: proposed targets of chemopreventive agents. (1995) (62)
- Intraepithelial neoplasia, surrogate endpoint biomarkers, and cancer chemoprevention (1993) (60)
- Colorectal Adenomas (2004) (60)
- Prostate-Specific Antigen Doubling Time as a Surrogate Marker for Evaluation of Oncologic Drugs to Treat Prostate Cancer (2004) (60)
- Surrogate endpoint biomarkers for phase II cancer chemoprevention trials. (1994) (59)
- K-ras mutations in lung tumors from A/J and A/J x TSG-p53 F1 mice treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and phenethyl isothiocyanate. (1995) (58)
- Strategies for identification and clinical evaluation of promising chemopreventive agents. (1996) (58)
- Biomarkers, Surrogate End Points, and the Acceleration of Drug Development for Cancer Prevention and Treatment (2004) (57)
- Enhancement of experimental colon carcinogenesis by dietary 6-phenylhexyl isothiocyanate. (1995) (56)
- Effects of theaflavins on N-nitrosomethylbenzylamine-induced esophageal tumorigenesis. (1997) (53)
- Use of in vitro assays to predict the efficacy of chemopreventive agents in whole animals (1996) (53)
- Difluoromethylornithine chemoprevention of epidermal carcinogenesis in K14-HPV16 transgenic mice. (1999) (52)
- Quantitative imaging for evaluation of response to cancer therapy. (2009) (52)
- Pilot studies evaluating the lung tumor yield in cigarette smoke-exposed mice. (2001) (52)
- Chemoprevention clinical trials. (1992) (51)
- Prognostic Value of Interim FDG-PET in Diffuse Large Cell Lymphoma: Results from the CALGB 50303 Clinical Trial. (2020) (50)
- Modulation of in vitro biomarkers of the carcinogenic process by chemopreventive agents. (1999) (49)
- Effects of novel phenylretinamides on cell growth and apoptosis in bladder cancer. (2001) (49)
- Properties of intraepithelial neoplasia relevant to the development of cancer chemopreventive agents (1997) (49)
- Chemopreventive effect of perillyl alcohol on 4‐(methylnitrosamino)‐1‐(3‐pyridyl)‐1‐butanone induced tumorigenesis in (C3H/HeJ X A/J)F1 mouse lung (1997) (49)
- Targeted imaging: an important biomarker for understanding disease progression in the era of personalized medicine. (2008) (48)
- Regulatory Approval of Cancer Risk-Reducing (Chemopreventive) Drugs: Moving What We Have Learned into the Clinic (2011) (48)
- Development of cancer chemopreventive drugs based on mechanistic approaches. (2005) (47)
- Induction of alopecia in mice exposed to cigarette smoke. (2000) (47)
- Intermediate biomarkers of precancer and their application in chemoprevention (1992) (47)
- Modulation of methylnitrosourea-induced breast cancer in Sprague Dawley rats by dehydroepiandrosterone: dose-dependent inhibition, effects of limited exposure, effects on peroxisomal enzymes, and lack of effects on levels of Ha-Ras mutations. (1998) (47)
- Temporal sequence of mammary intraductal proliferations, ductal carcinomas in situ and adenocarcinomas induced by 1-methyl-1-nitrosourea in rats. (1998) (46)
- Clinical development plan: N-(4-hydroxyphenyl)retinamide. (1994) (45)
- Assessing the barriers to image-guided drug delivery. (2014) (45)
- Chemoprevention of OH-BBN-induced bladder cancer in mice by oltipraz, alone and in combination with 4-HPR and DFMO. (1994) (45)
- Assay of C-type virus infectivity by measurement of RNA-dependent DNA polymerase activity. (1972) (45)
- Prostate cancer prevention: investigational approaches and opportunities. (1996) (44)
- Focal adhesion kinase (FAK) phosphorylation is not required for genistein-induced FAK-β-1-integrin complex formation (2004) (44)
- Murine C-type RNA Virus from Spontaneous Neoplasms: in vitro Host Range and Oncogenic Potential (1973) (44)
- International liquid biopsy standardization alliance white paper. (2020) (44)
- Mechanistic considerations in the evaluation of chemopreventive data. (1996) (44)
- Naturally occurring sarcoma virus of the BALB/cCr mouse. (1974) (43)
- Hamster-tropic sarcomagenic and nonsarcomagenic viruses derived from hamster tumors induced by the Gross pseudotype of Moloney sarcoma virus. (1970) (43)
- Recent results in preclinical and clinical drug development of chemopreventive agents at the National Cancer Institute. (1993) (43)
- Potential use of lipoxygenase inhibitors for cancer chemoprevention (2000) (43)
- Effect of the chemopreventive agents piroxicam and D,L-alpha-difluoromethylornithine on intermediate biomarkers of colon carcinogenesis. (1992) (43)
- Transformation of rat and hamster embryo cells by extracts of city smog. (1971) (42)
- Clinical development plans for cancer chemopreventive agents (1996) (41)
- Chemopreventive effects of the aromatase inhibitor vorozole (R 83842) in the methylnitrosourea-induced mammary cancer model. (1998) (41)
- Chemoprevention of bladder cancer (1987) (41)
- Surrogate anatomic/functional sites for evaluating cancer risk: an extension of the field effect. (1999) (40)
- Farnesyl protein transferase inhibitors as potential cancer chemopreventives. (1997) (40)
- Evaluation of Biomarker Modulation by Fenretinide in Prostate Cancer Patients (1999) (38)
- Selection of cancer chemopreventive agents based on inhibition of topoisomerase II activity. (2000) (38)
- Inhibition of 2-Amino-1-methyl-6-phenylimidazo[4,5]pyridine-induced lymphoma formation by oltipraz. (1996) (38)
- Intermediate biomarkers of colon cancer: modulation of expression of ras oncogene by chemopreventive agents during azoxymethane induced colon carcinogenesis. (1993) (37)
- Properties of Intraepithelial Neoplasia Relevant to Cancer Chemoprevention and to the Development of Surrogate End Points for Clinical Trials (1997) (37)
- Activation and isolation of hamster-specific C-type RNA viruses from tumors induced by cell cultures transformed by chemical carcinogens. (1971) (37)
- Chemo- and dietary prevention of colorectal cancer. (1995) (36)
- Chemoprevention of MNU-induced mammary tumorigenesis by hormone response modifiers: toremifene, RU 16117, tamoxifen, aminoglutethimide and progesterone. (1994) (36)
- Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites. (2003) (35)
- A quantitative angiogenesis model for efficacy testing of chemopreventive agents. (2001) (34)
- Regulatory and reimbursement challenges for molecular imaging. (2007) (33)
- Identification of retinamides that are more potent than N-(4-hydroxyphenyl)retinamide in inhibiting growth and inducing apoptosis of human head and neck and lung cancer cells. (2001) (33)
- Chemopreventive potential of fumaric acid, N-acetylcysteine, N-(4-hydroxyphenyl) retinamide and beta-carotene for tobacco-nitrosamine-induced lung tumors in A/J mice. (1998) (33)
- Intraepithelial and postinvasive neoplasia as a stochastic continuum of clonal evolution, and its relationship to mechanisms of chemopreventive drug action (1993) (32)
- Development of chemopreventive agents for bladder cancer (1992) (31)
- Cytokeratin, lectin, and acidic mucin modulation in differentiating colonic epithelial cells of mice after feeding Western-style diets. (1996) (31)
- Differential response of normal, premalignant and malignant human oral epithelial cells to growth inhibition by chemopreventive agents. (2000) (31)
- Preclinical efficacy studies of green and black tea extracts. (1999) (31)
- Development of new cancer chemoprevention agents: role of pharmacokinetic/pharmacodynamic and intermediate endpoint biomarker monitoring. (1998) (30)
- Chemoprevention by indomethacin of N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder tumors. (1993) (30)
- Natural immunity in mice to structural polypeptides of endogenous type C RNA viruses (1976) (30)
- Oltipraz, a novel inhibitor of hepatitis B virus transcription through elevation of p53 protein. (1998) (30)
- A QA Program for MRD Testing Demonstrates That Systematic Education Can Reduce Discordance Among Experienced Interpreters (2018) (29)
- Immunological identity of the group-specific antigen of hamster-specific C-type viruses and an indigenous hamster virus. (1970) (29)
- Induction of atypical ductal hyperplasia in mouse mammary gland organ culture. (2001) (29)
- Immunoprevention of x-ray-induced leukemias in the C57BL mouse. (1977) (29)
- 9-cis-retinoic acid but not 4-(hydroxyphenyl)retinamide inhibits prostate intraepithelial neoplasia in Noble rats. (2002) (29)
- Envelope antigen relationships among three hamster-specific sarcoma viruses and a hamster-specific helper virus. (1970) (29)
- Assessing intraepithelial neoplasia and drug safety in cancer-preventive drug development (2007) (28)
- Chemoprevention (1995) (27)
- Expression of cell cycle proteins in 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung tumors. (1998) (27)
- Strategies for phase II cancer chemoprevention trials: Cervix, endometrium, and ovary (1995) (27)
- Influence of thiols and inhibitors of prostaglandin biosynthesis on the carcinogen-induced development of mammary lesions in vitro. (1991) (27)
- Preclinical drug development paradigms for chemopreventives. (1998) (27)
- Chemopreventive effect of S-methylmethane thiosulfonate and sulindac administered together during the promotion/progression stages of colon carcinogenesis. (1999) (27)
- Effects of oltipraz and related chemoprevention compounds on gene expression in rat liver (1995) (27)
- Chemoprevention of exprimental bladder cancer (1992) (27)
- FDG-PET lymphoma demonstration project invitational workshop. (2007) (27)
- Neoplastic transformation of mammary epithelial cells in rats is associated with decreased apoptotic cell death. (2000) (27)
- Development of chemopreventive agents for lung and upper aerodigestive tract cancers (1993) (26)
- Novel translational model for breast cancer chemoprevention study: accrual to a presurgical intervention with tamoxifen and N-[4-hydroxyphenyl] retinamide. (2000) (26)
- Introductory remarks: Development of chemopreventive agents for prostate cancer (1992) (26)
- Effect of calcium on azoxymethane-induced aberrant crypt foci and cell proliferation in the colon of rats. (1998) (26)
- Suppression of cell proliferation and telomerase activity in 4-(hydroxyphenyl)retinamide-treated mammary tumors. (1999) (26)
- Chemoprevention of respiratory-tract neoplasia in the hamster by oltipraz, alone and in combination. (1994) (25)
- Interspecies analysis of the chemopreventive efficacy of dietary alpha-difluoromethylornithine. (1990) (25)
- Hamster lung cancer model of carcinogenesis and chemoprevention. (1992) (25)
- Termination of piroxicam treatment and the occurrence of azoxymethane-induced colon cancer in rats. (1999) (25)
- Development of breast cancer chemopreventive drugs (1993) (24)
- Lack of chemopreventive efficacy of DL-selenomethionine in colon carcinogenesis. (2000) (24)
- Biomarker end-points in cancer chemoprevention trials. (1997) (24)
- Inhibition of cigarette smoke-related DNA adducts in rat tissues by indole-3-carbinol. (2000) (24)
- N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells. (2005) (23)
- Workshop on imaging science development for cancer prevention and preemption. (2006) (23)
- Comparative activity of N-(4-hydroxyphenyl)-all-trans-retinamide and alpha-difluoromethylornithine as inhibitors of lymphoma induction in PIM transgenic mice. (1996) (22)
- Immunity to virus-free syngeneic tumor cell transplantation in the BALB/c mouse after immunization with homologous tumor cells infected with type C virus. (1976) (22)
- Biomarker development in the context of urologic cancers. (2015) (22)
- Screening of potential cancer preventing chemicals for induction of glutathione in rat liver cells. (1998) (21)
- Intermediate endpoint biomarkers for chemoprevention (1992) (21)
- Chemoprevention and modern cancer prevention. (1989) (21)
- Chemoprevention of prostate cancer: Guidelines for possible intervention strategies (1992) (21)
- Development of surrogate endpoint biomarkers for clinical trials of cancer chemopreventive agents: relationships to fundamental properties of preinvasive (intraepithelial) neoplasia. (1994) (20)
- Cellular responses of mammary carcinomas to aromatase inhibitors: Effects of vorozole (2000) (20)
- Statistical analysis of animal cancer chemoprevention experiments. (1993) (20)
- An approach to C-type virus immunoprevention of spontaneously occurring tumors in laboratory mice. (1976) (20)
- Quantitative grading of rat esophageal carcinogenesis using computer-assisted image tile analysis. (2000) (20)
- Inactivation of murine sarcoma and leukemia viruses by ultra-violet irradiation. (1970) (20)
- Neoplasm induction by murine type-C viruses passaged directly from spontaneous non-lymphoreticular tumours. (1973) (18)
- Inhibition of Chemical Carcinogenesis (1995) (18)
- In vivo Studies of the FBJ Murine Osteosarcoma Virus (1969) (18)
- Naturally occurring lymphocyte-mediated immunity to endogenous type-C virus in the mouse. Blocking of the lymphocyte reactivity with antisera to the virus (1979) (18)
- Chronic toxicity studies of the potential cancer preventive 2-(difluoromethyl)-dl-ornithine. (1994) (18)
- Prevalence of endogenous type-C virus in normal hamster tissues and hamster tumors induced by chemical carcinogens, simian virus 40, and polyoma virus. (1974) (18)
- Reanalysis of Cancer Drugs (2004) (18)
- Effect of reduced body weight gain on the evaluation of chemopreventive agents in the methylnitrosourea-induced mammary cancer model. (1999) (18)
- Chemoprevention of experimental bladder cancer. (1992) (18)
- The natural history of intraepithelial neoplasia: Relevance to the search for intermediate endpoint biomarkers (1992) (17)
- Histologic characterization of mouse bronchiolar cell hyperplasia, metaplasia, and neoplasia induced intratracheally by 3-methylcholanthrene. (1991) (17)
- The role of chemoprevention in cancer control. (1996) (16)
- Detection of differentially expressed genes in mouse lung adenocarcinomas. (2001) (16)
- Monoclonal antibodies specific to transforming polyproteins encoded by independent isolates of feline sarcoma virus (1982) (16)
- State of the Science and Future Directions for Liquid Biopsies in Drug Development. (2020) (16)
- Replication of Murine and Feline RNA-containing C-type Viruses in Human Lymphoblastoid Cells (1970) (16)
- Prevention and early detection of lung cancer-clinical aspects. (1997) (16)
- Cancer chemoprevention: progress and promise. (1999) (16)
- Quantitation of preinvasive neoplastic progression in animal models of chemical carcinogenesis (1997) (16)
- Clinical Development Plan (2020) (15)
- Chromosome 3p tumor‐suppressor gene alterations in cervical carcinomas (2001) (15)
- Effect of chemopreventive agents on intermediate biomarkers during different stages of azoxymethane-induced colon carcinogenesis. (1992) (15)
- Bcl-2 and Bax are differentially expressed in hyperplastic, premalignant, and malignant lesions of mammary carcinogenesis. (2000) (15)
- Bayesian monitoring of phase II trials in cancer chemoprevention. (1999) (15)
- Tissue-specific expression of the K-ras allele from the A/J parent in (A/J x TSG-p53) F1 mice. (1997) (14)
- Mammary tumors, hepatocellular carcinomas, and pancreatic islet changes in C3H-Avy Mice. (1978) (14)
- Development of Breast Cancer Chemopreventive Drugs (1995) (14)
- Clinical development plan: N-Acetyl-l-cysteine. (1994) (14)
- Inhibition of cigarette smoke-related lipophilic DNA adducts in rat tissues by dietary oltipraz. (1998) (14)
- Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration (2021) (14)
- A comparative analysis of allelic imbalance events in chemically induced rat mammary, colon, and bladder tumors (1999) (14)
- Opportunities and Challenges in Implementation of Multiparameter Single Cell Analysis Platforms for Clinical Translation (2018) (14)
- Oncogenic potential of murine C-type RNA virus passaged directly from naturally occurring tumors of the BALB-cCr mouse. (1973) (14)
- Surrogate end-point biomarkers in chemopreventive drug development. (2001) (14)
- Effects of dietary supplementation of N-acetylcysteine on cigarette smoke-related DNA adducts in rat tissues. (1997) (14)
- Promising cancer chemopreventive agents (2004) (14)
- Preclinical Efficacy Studies of Green and Black Tea Extracts (1999) (14)
- Clinical development plan: 2‐Difluoromethylornithine (DFMO) (1994) (13)
- Advances in Brief The Cyclooxygenase-2 Inhibitor Celecoxib Is a Potent Preventive and Therapeutic Agent in the Min Mouse Model of Adenomatous Polyposis 1 (2000) (13)
- Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers. (2003) (13)
- Screening of potential cancer-preventing chemicals for inhibition of induction of ornithine decarboxylase in epithelial cells from rat trachea. (1998) (13)
- Animal models for chemoprevention of respiratory cancer. (1992) (13)
- Natural occurrence of tumors in mouse strains with different xenotropic and ecotropic endogenous viruses. (1976) (13)
- Clinical development plan: Vitamin E (1994) (13)
- The human epithelial cell cytotoxicity assay for determining tissue specific toxicity. (2000) (13)
- Induction of sugar uptake by a hamster pseudotype sarcoma virus. (1971) (12)
- The development of an anchorage-independence assay using human lung tumor cells to screen potential chemopreventive agents. (1996) (12)
- Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology. (2018) (12)
- Chemoprevention of azoxymethane-induced colon cancer by ascorbylpalmitate, carbenoxolone, dimethylfumarate and p-methoxyphenol in male F344 rats. (1995) (12)
- Chronic toxicity studies of 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione, a potential chemopreventive agent. (1997) (11)
- Seeing into cells (2005) (11)
- Clinical development of estrogen modulators for breast cancer chemoprevention in premenopausal vs. postmenopausal women (2000) (11)
- Prostate intraepithelial neoplasia in Noble rats, a potential intermediate endpoint for chemoprevention studies. (2004) (11)
- Bayesian monitoring of a phase 2 chemoprevention trial in high-risk cohorts for prostate cancer. (2001) (11)
- Chemoprevention strategies in the prostate: an overview. (2002) (10)
- Assay in the mouse for delayed-type hypersensitivity to murine leukemia virus. (1975) (10)
- Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health (2021) (10)
- RNA tumor virus genomes as determinants of chemically-induced transformation in vitro. (1973) (10)
- Biomarkers of Premalignant Breast Disease and Their Use as Surrogate Endpoints in Clinical Trials of Chemopreventive Agents (1995) (10)
- Study of postnatal effects of chemopreventive agents on offspring of ethylnitrosourea-induced transplacental carcinogenesis in rats. I. Influence of retinol acetate, alpha-tocopherol acetate, thiamine chloride, sodium selenite, and alpha-difluoromethylornithine. (1991) (9)
- Early Detection of Oral Neoplasia: Watching with New Eyes (2009) (9)
- Strategy and planning for chemopreventive drug development: clinical development plans. Chemoprevention Branch and Agent Development Committee. National Cancer Institute. (1994) (9)
- Differences in tumor incidence in two substrains of Claude BALB/c (BALB/cfCd) mice, emphasizing renal, mammary, pancreatic, and synovial tumors. (1976) (9)
- New directions in dietary studies in cancer: the National Cancer Institute. (1995) (8)
- Effects of acute and chronic body weight gain reductions in the evaluation of agents for efficacy in mammary cancer prevention. (2001) (8)
- Screening of potential cancer preventing chemicals as aromatase inhibitors in an in vitro assay. (1999) (7)
- Chronic Toxicity Studies of 5-(2-Pyrazinyl)-4-methyl-1,2-dithiole- 3-thione, a Potential Chemopreventive Agent (1997) (7)
- Detection of differentially expressed genes in Methylnitrosourea‐induced rat mammary adenocarcinomas (1997) (7)
- Guidance for development of chemopreventive agents (1994) (7)
- Inherited susceptibility and acquired allelic imbalance in rat mammary carcinogenesis (1996) (7)
- Selection criteria for breast cancer chemoprevention subjects (1993) (7)
- Clinical development plan: Sulindac (1994) (7)
- The Chemoprevention Program of the National Cancer Institute (1986) (6)
- Chemoprevention with theaflavins of rat esophageal intraepithelial neoplasia quantitatively monitored by image tile analysis. (2000) (6)
- Intervention and Chemoprevention of Cancer (2005) (6)
- Isolation of helper viruses from preparations of hamster-specific sarcoma viruses. (1971) (6)
- Modulation of Ki67, p53 and RARbeta expression in normal, premalignant and malignant human oral epithelial cells by chemopreventive agents. (2001) (6)
- Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation (2020) (6)
- Intracellular localization of mammalian type C virus species-specific (gs-1) and interspecies-specific (gs-3) antigenic determinants with the indirect immunoperoxidase technique and light microscopy. (1973) (6)
- Chemoprevention strategies utilizing combinations of inhibitors of carcinogenesis. (1989) (6)
- CANCER CHEMOPREVENTION DRUG DEVELOPMENT STRATEGIES FOR RESVERATROL (1998) (6)
- Immunofluorescent detection of murine and hamster C‐type virus species‐specific (gs‐1) determinants by monospecific guinea‐pig sera and interspecies‐specific (gs‐3) determinants by tumor‐bearing rat sera (1971) (5)
- Modulation of alterations in p53 tumor suppressor gene and its association with activation of ras proto-oncogenes during chemoprevention of colon cancer. (1997) (5)
- Chemoprevention of Cancer by NSAIDs and Selective COX-2 Blockade (2003) (5)
- Chemoprevention of Cancer: Implications for Clinical Pharmacology (1985) (5)
- Type‐C virus structural antigens on the surface of the infected cell as determined by a humoral cytotoxicity assay (1978) (5)
- Seeing into cells. The promise of in vivo molecular imaging in oncology. (2005) (5)
- Clinical development plan: 18beta-glycyrrhetinic acid. (1994) (5)
- Correlation of chemopreventive efficacy data from the human epidermal cell assay with in vivo data. (2000) (5)
- Clinical development plan: beta-carotene and other carotenoids. (1994) (4)
- Chemoprevention of DMBA-induced Mammary Carcinogenesis: Relationship Between Induction of Phase II Enzymes, Effects on DMBA-induced Hemoglobin Adducts and Decreases in Mammary Tumor Multiplicity (2000) (4)
- Effects of Dehydroepiandrosterone on MNU‐Induced Breast Cancer in Sprague‐Dawley Rats (1995) (4)
- Naturally occurring humoral immunity to endogenous xenotropic and amphotropic type‐C virus in the mouse (1981) (4)
- Foreword: Potential of Optical Imaging for Early Cancer Detection, Screening, Diagnosis and Image Guided Treatment (2003) (4)
- Clinical development plan: Tamoxifen (1994) (4)
- Retention of antigen specificity of murine sarcoma viruses grown in hamster cells in vitro. (1971) (4)
- Clinical development plan: Oltipraz (1994) (4)
- Clinical development plan: Aspirin (1994) (4)
- Perspectives on chemoprevention agent selection and short-term clinical prevention trials. (1996) (4)
- Effect of early vs. late administration of 4‐Hydroxyphenylretinamide (4‐HPR) on N‐Methyl‐N‐Nitrosourea (MNU)‐induced mammary tumorigenesis (1997) (4)
- Detection of genomic alterations in human cervical cancer by two‐dimensional gel electrophoresis (1996) (3)
- NSAID trials, sporadic adenomas, and conservative inferences. (1996) (3)
- Development of a lymphocyte transformation microassay for murine leukemia virus. (1976) (3)
- Research studies on chemoprevention of esophageal cancer at the United States National Cancer Institute. (1993) (3)
- Screening of potential cancer preventing chemicals as antioxidants in an in vitro assay. (1998) (3)
- Immunoprevention of naturally occurring endogenous murine type-C RNA viruses (1978) (3)
- Clinical development plan: Proscar. (1994) (3)
- Endpoint markers for cancer chemoprevention trials derived from the lesion of precancer (intraepithelial neoplasia) measured by computer‐assisted quantitative image analysis (2000) (3)
- Chemopreventive potential of fumaric acid, N-acetylcysteine, N-(4-hydroxyphenyl) retinamide and β-carotene for tobacco-nitrosamine-induced lung tumors in A/J mice1This is paper 27 in the series `Dietary Inhibitors of Chemical Carcinogenesis'.1 (1998) (3)
- Clinical development plan: Piroxicam (1994) (3)
- DNA quantification in cervical intraepithelial neoplasia thick tissue sections by confocal laser scanning microscopy (1996) (3)
- Perspectives and progress in development of breast cancer chemopreventive drugs. (1997) (3)
- Rationale for the selection and use of in vitro assays to screen for chemopreventive agents (1997) (2)
- Endpoint markers for clinical trials of chemopreventive agents derived from the properties of epithelial precancer (intraepithelial neoplasia) measured by computer-assisted image analysis. (1998) (2)
- Development of new cancer chemoprevention agents (1998) (2)
- In vitro chemopreventive efficacy screening using human keratinocytes and the in vivo data correlation. (1999) (2)
- DETECTION OF GENETIC ALTERATIONS IN MOUSE LUNG ADENOCARCINOMAS BY TWO-DIMENSIONAL GEL ELECTROPHORESIS (2000) (2)
- Clinical development plan: Calcium (1994) (2)
- Isolation and characterization of the hamster C-type viruses. (1973) (2)
- The effect of celecoxib on duodenal polyposis in familial adenomatous polyposis (FAP) (2000) (2)
- Effect of sulindac sulfone on proliferation, apoptosis, and polyps in a clinical trial in familial adenomatous polyposis (FAP) with rectal polyps* (1998) (2)
- Chemoprevention of lung cancer. Problems and progress. (1989) (2)
- Clinical development plan: Ibuprofen (1994) (2)
- Chemoprevention of rat mammary carcinogenesis: Exceptional activity of dietary dehydroepiandrosterone (DHEA) (1993) (2)
- Symposium : Diet , Natural Products and Cancer Prevention : Progress and Promise Progress in Cancer Chemoprevention : Development of Diet-Derived Chemopreventive Agents 1 (2000) (2)
- Experience with MRD Testing in B- ALL By Flow Cytometry Does Not Prevent Interpretative Discordance (2016) (2)
- Precancerous lesions of the digestive tract: The 18th Annual Symposium of the European Cancer Prevention Organisation Maastricht, The Netherlands, 12-14 October 2000 (2000) (2)
- Prostatitis and Urethritis (1999) (1)
- Intervention and Chemoprevention of Cancer – Treatment of Carcinogenesis (2007) (1)
- Oncologic Drug Development The Progress and Promise of Molecular Imaging Probes in (2005) (1)
- Clinical development plan: Vitamin D3 and analogs (1994) (1)
- Arachidonic Acid Pathway in Cancer Prevention (2003) (1)
- Prostatitis and Urethritis (1999) (1)
- Challenges to Using Big Data in Cancer (2023) (1)
- Monoclonal antibodies to feline sarcoma virus gag and fes gene translational products (1983) (1)
- Advances in Brief Chemoprevention of Rat Prostate Carcinogenesis by 9-cis-Retinoic Acid 1 (1999) (1)
- Sensitive in vivo assay for detection of murine leukemia viruses. (1974) (1)
- Use of Druckrey analysis to quantitatively evaluate the chemopreventive efficacy of N-difluoromethylornithine (DFMO), a prototype proliferation inhibitor. (1998) (1)
- Molecular Imaging and the Microenvironment (2001) (1)
- Endpoint markers for cancer chemoprevention trials derived from the lesion of precancer (intraepithelial neoplasia) measured by computer-assisted quantitative image analysis. (2000) (1)
- Morphometric Nuclear Grading of Intraepithelial Neoplastic Lesions with Applications to Cancer Chemoprevention Trials 1 (1999) (1)
- Considerations in the development of circulating tumor cell technology for clinical use (2012) (1)
- Sensitive In Vivo Assay for Detection of Murine Leukemia Viruses (1974) (0)
- Congressional update: report from the Biomedical Imaging Program of the National Cancer Institute. Molecular imaging and the microenvironment. (2001) (0)
- Qualification of FDG PET/CT as an oncologic biomarker: A methodology demonstration for lymphoma (2012) (0)
- Umbrella Test the effect of one or more drugs on one or more single mutations in a variety of cancer types Test the impact of different drugs on different mutations in a single type of cancer Basket (2015) (0)
- Subject Index Vol. 35, 1999 (1999) (0)
- Molecular Target Based Discovery and Development of Chemopreventive Drugs (2000) (0)
- Transferases S Induction of Glutathione Chemoprevention of Aflatoxin-induced Tumorigenesis and Intermittent Dosing with Oltipraz : Relationship between Updated Version (2006) (0)
- Combination-Fluoro-5-androsten-17-one , and Ellagic Acid Individually and in α-Difluoromethylornithine , 16 α Administration of Piroxicam , Chemoprevention of Colon Carcinogenesis by Dietary Updated (2006) (0)
- Chemoprevention of Colon Carcinogenesis by Organosulfur Compounds 1 (2006) (0)
- Subject Index Vol. 35, 1999 (1999) (0)
- Antiinflammatories and Chemoprevention (2004) (0)
- Chemoprevention of premalignant and early malignant lesions of the bladder. (1992) (0)
- RFA: CA-03-002 Network for Translational Research: Optical Imaging (2002) (0)
- Efficacy of Ethylvanillin in the Prevention of Mammary Tumors Induced by Methylnitrosourea (MNU) in the Rats (1994) (0)
- Perillyl alcohol has a chemopreventive effect on 4- -1- -1-butanone induced tumorigenesis in C3A F-1 mouse lung (1997) (0)
- Structural antigens on the surface of type-c virus and on virus-infected cells. Abstr. (1977) (0)
- A Multi-Institutional Biomarker Study of Large B-cell Lymphomas in FDG PET/CT - Experiences within the Oncology Biomarker Qualification Initiative (OBQI) (2016) (0)
- RFA:CA-03-002: network for translational research: optical imaging. (2002) (0)
- Induction of apoptosis by 1,4-phenylenebis seleno-cyanate in cultured human colon cancer cells (1999) (0)
- Blocking of natural killer cell mediated cytotoxicity with normal serum-antibody. Abstr. (1979) (0)
- PROGRESS IN CANCER CHEMOPREVENTION Inhibit Carcinogen Uptake Inhibit Carcinogen Formation Deactivate Carcinogen Restore Normal Cell Growth / Differentiation Modulate Signal Transduction Pathways Inhibit Poh / amine Metabolism Inhibit Arachidonic (2006) (0)
- Early response metrics for predicting trial outcomes: A report from volumetric CT for precision analysis of clinical trials (Vol-PACT). (2018) (0)
- Surrogate endpoint biomarker (SEB) guided drug development: A practical strategy for chemoprevention(CP) of preinvasive cancer (PRECA) (1997) (0)
- Advances in Brief Chemoprevention of Pulmonary Carcinogenesis by Aerosolized Budesonide in Female A / J Mice 1 (2006) (0)
- Histopathology of human intraepithelial neoplasia with implications for chemoprevention strategy. (1993) (0)
- Influence of W-Methyl-W-Nitrosourea, Testosterone, and A^-(4-Hydroxyphenyl)-all- ¿ra/is-retinamide on Prostate Cancer Induction in Wistar-Unilever Rats1 (2006) (0)
- Breast cancer chemoprevention clinical trials (1993) (0)
- The Influence of Randomized Controlled Cancer Chemoprevention Trials on the Evolution of Regulatory Assessments (2011) (0)
- Case Studies for Overcoming Challenges in Using Big Data in Cancer (2023) (0)
- Overview of precancer and goals of the meeting (2006) (0)
- Assessment of circulating tumor cell number as a transitional surrogate endpoint for survival in phase II trials for metastatic castration-resistant prostate cancer. (2019) (0)
- Opportunities for collaboration on imaging development in NCI programs (2006) (0)
- Clinical development plan: DHEA analog 8354 (1994) (0)
- Vol. 35, 1999 (1999) (0)
- Chemotherapeutic Agents Taxol or Adriamycin-Inositol and myo Agents Green Tea or Dexamethasone / ChemopreventiveTumorigenesis : p 53-independent Efficacy of Mutation Accelerates Pulmonary p 53 A GermLine Updated (2000) (0)
- Vol. 35, 1999 (1999) (0)
- Treatment and Prevention of Intraepithelial Neoplasia : An Important Target for Accelerated New Agent Development Recommendations of the American Association for Cancer Research Task Force on the Treatment and Prevention of Intraepithelial Neoplasia 1 (2002) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Gary, J. Kelloff?
Gary, J. Kelloff is affiliated with the following schools:
